Home › Non-Small Cell Lung Cancer › Delaware › Newark
Non-Small Cell Lung Cancer clinical trials in Newark, DE
15 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RecruitingPhase 3
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Newark
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Medical Oncology Hematology Consultants, PA, Newark
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RecruitingPhase 3
- Medical Oncology Hematology Consultants, PA, Newark
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- Christiana Care - Union Hospital, Elkton · 7 mi away
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Newark
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RecruitingPhase 3
- Medical Oncology Hematology Consultants, PA, Newark
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- ChristianaCare Health System, Newark
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Medical Oncology Hematology Consultants, Newark
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RecruitingPhase 3
- Research Site, Newark
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Newark
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX143 studies
- New York City, NY123 studies
- Arlington, VA111 studies
- Nashville, TN97 studies
- Los Angeles, CA92 studies
- Boston, MA87 studies
- St. Louis, MO68 studies
- Baltimore, MD60 studies
- San Antonio, TX60 studies
- Chicago, IL59 studies
- Columbus, OH57 studies
- Seattle, WA55 studies
Other studies in Newark
- Prostate Cancer10 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Metastatic Cancer8 studies
- Breast Cancer8 studies
- Pancreatic Cancer6 studies
- Cancer (all types)6 studies
- Ovarian Cancer5 studies
- Bladder Cancer4 studies
- Chronic Lymphocytic Leukemia4 studies
- Stomach Cancer4 studies
- Melanoma4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.